Compare Quanterix Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 221 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.40
-25.81%
0.70
Revenue and Profits:
Net Sales:
44 Million
(Quarterly Results - Dec 2025)
Net Profit:
-23 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.18%
0%
-40.18%
6 Months
-25.28%
0%
-25.28%
1 Year
-44.92%
0%
-44.92%
2 Years
-83.03%
0%
-83.03%
3 Years
-62.57%
0%
-62.57%
4 Years
-86.13%
0%
-86.13%
5 Years
-92.4%
0%
-92.4%
Quanterix Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.32%
EBIT Growth (5y)
-198.58%
EBIT to Interest (avg)
-54.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.38
Tax Ratio
5.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.70
EV to EBIT
-0.97
EV to EBITDA
-1.14
EV to Capital Employed
0.50
EV to Sales
0.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-51.63%
ROE (Latest)
-25.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 48 Schemes (38.3%)
Foreign Institutions
Held by 86 Foreign Institutions (20.8%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
43.90
40.20
9.20%
Operating Profit (PBDIT) excl Other Income
-16.60
-23.50
29.36%
Interest
0.00
0.00
Exceptional Items
-0.30
-7.10
95.77%
Consolidate Net Profit
-23.10
-33.50
31.04%
Operating Profit Margin (Excl OI)
-544.20%
-749.40%
20.52%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 9.20% vs 64.08% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 31.04% vs -11.67% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
138.90
137.40
1.09%
Operating Profit (PBDIT) excl Other Income
-68.50
-44.30
-54.63%
Interest
0.00
0.00
Exceptional Items
-33.60
0.00
Consolidate Net Profit
-107.10
-38.50
-178.18%
Operating Profit Margin (Excl OI)
-629.40%
-382.90%
-24.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.09% vs 12.25% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -178.18% vs -35.56% in Dec 2024
About Quanterix Corp. 
Quanterix Corp.
Pharmaceuticals & Biotechnology
Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.
Company Coordinates 
Company Details
900 Middlesex Tpke , BILLERICA MA : 01821-3929
Registrar Details






